Sentynl Therapeutics and Mereo BioPharma have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase III and, if approved, would be the first oral treatment for the rare, progressive genetic […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!